Saturday, October 19, 2024 | ||
---|---|---|
2:15 PM - 2:30 PM | Joint ILCA-AASLD-CASL Symposium | Strategies for HCC prevention, including in non-viral liver disease |
2:30 PM - 2:45 PM | Joint ILCA-AASLD-CASL Symposium | Emerging approaches to HCC surveillance |
2:45 PM - 3:00 PM | Joint ILCA-AASLD-CASL Symposium | Precision surveillance: close to reality? |
3:00 PM - 3:15 PM | Joint ILCA-AASLD-CASL Symposium | Recall systems and linkage to care: Important steps after surveillance |
3:15 PM - 3:30 PM | Joint ILCA-AASLD-CASL Symposium | System- and population-level approaches to prevention and surveillance |
5:15 PM - 5:25 PM | Opening Remarks from CASL President | |
5:25 PM - 5:30 PM | Opening Remarks from Canadian Liver Foundation | |
5:30 PM - 6:00 PM | Keynote Speaker Lecture | State of the Art: Towards an AI-Driven Precision Medicine approach in Hepatocellular Carcinoma |
6:00 PM - 7:00 PM | Welcome Reception + Networking | |
Sunday, October 20, 2024 | ||
7:30 AM - 9:00 AM | Breakfast | |
8:00 AM - 8:45 AM | Industry Breakfast Symposium | |
9:00 AM | Epidemiology/Diagnosis/Staging - Moderated by | |
9:00 AM - 9:15 AM | Epidemiology/Diagnosis/Staging | Epidemiology: The burden of HCC in Canada |
9:15 AM - 9:30 AM | Epidemiology/Diagnosis/Staging | Diagnostic: The best modality to diagnose HCC |
9:30 AM - 9:45 AM | Epidemiology/Diagnosis/Staging | Staging: Utility of the BCLC staging system |
9:45 AM - 10:00 AM | Epidemiology/Diagnosis/Staging | Advances in Multidisciplinary Tumor Board Rounds (MTBR) |
10:00 AM - 10:15 AM | Epidemiology/Diagnosis/Staging | Q&A |
10:15 AM - 10:45 AM | Coffee Break | |
10:45 AM | Early & Intermediate HCC - Moderated by | |
10:45 AM - 11:00 AM | Early & Intermediate HCC | Surgery as first line therapy |
11:00 AM - 11:15 AM | Early & Intermediate HCC | How/When/Why liver transplant for HCC |
11:15 AM - 11:30 AM | Early & Intermediate HCC | The role of SBRT in HCC management |
11:30 AM - 11:45 AM | Early & Intermediate HCC | The role of LRT in HCC cure |
11:45 AM - 12:00 PM | Early & Intermediate HCC | Q&A |
12:00 PM - 1:15 PM | Lunch | |
12:00 PM - 1:15 PM | Industry Lunch Symposium | |
1:15 PM | Late HCC & Palliative Care - Moderated by | |
1:15 PM - 1:30 PM | Late HCC & Palliative Care | Post transplant management of HCC liver transplant recipients |
1:30 PM - 1:45 PM | Late HCC & Palliative Care | How to use IO therapy |
1:45 PM - 2:00 PM | Late HCC & Palliative Care | Use of biomarker in predicting response to treatment |
2:00 PM - 2:15 PM | Late HCC & Palliative Care | Utility of Palliative Care in HCC care. When is too early? |
2:15 PM - 2:30 PM | Late HCC & Palliative Care | Q&A |
2:30 PM - 3:00 PM | Afternoon Break | |
3:00 PM | Future Directions - Moderated by | |
3:00 PM - 3:15 PM | Future Directions | The Importance and Impact of Cancer Research in Canada |
3:15 PM - 3:30 PM | Future Directions | How to incorporate the patient voice in HCC care |
3:30 PM - 3:45 PM | Future Directions | The future of AI in HCC |
3:45 PM - 4:00 PM | Future Directions | Q&A |
4:00 PM - 4:15 PM | Closing Remarks |